Background Low-grade gangliogliomas/gangliocytomas (GG) are rare tumors of the CNS, which occur mostly in young people. Due to their rarity, large-scale, population-based studies focusing on epidemiology and outcomes are lacking. Objective To use the Surveillance, Epidemiology, and End Results (SEER) datasets of the National Cancer Institute to study demographics, tumor location, initial treatment, and outcome data on low-grade GG in children. Methods SEER-STAT v8.1.2 identified all patients aged 0-19 years in the SEER datasets with low-grade GGs. Using the Kaplan-Meier method and Cox proportional hazard regression, we examined associations between these characteristics and survival. Results There were 348 children with low-grade GG diagnosed from 2004-2010, with a median follow-up of 37 months. Tumors were more prevalent in males (n=208, 59.8%) than females (n=140, 40.2%) (p<0.001). Almost 63% percent occurred in children >10 years, while only 3.5% were found in those <1 year old. Approximately 50% were located in the temporal lobes, while only 3.7% and 3.5% were located in the brainstem and spinal cord, respectively. Surgery was performed on 91.6% of cases, with gross total resection (GTR) achieved in 68.3%. Radiation was used in 3.2%. Young age (<1yrs) and brainstem location were associated with worse overall survival (OS). Conclusion This study shows that low-grade GG occur in older children with a male preference. GTR is achieved in the majority of cases, and radiation is rarely used. While the majority of patients have an excellent prognosis, infants and patients with brainstem tumors have worse survival rates.
Choroid plexus papillomas (CPPs) and carcinomas (CPCs) are rare neoplasms that affect mostly children. Due to their rarity, their epidemiology and outcomes are incompletely understood. The National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program is a well-established population-based group of registries that collects and publishes cancer incidence and survival data representing approximately 28 % of the US population. SEER-STAT v8.1.2 was used to identify patients with ICD-O-3 codes for choroid plexus tumors in patients aged 0-19. Demographics, initial treatment, and follow-up data were collected. Statistical methods including Kaplan-Meier curves, log rank tests, and Cox proportional hazards regression were used to estimate associations between independent variables and survival. The SEER registries contained 107 CPPs (2004-2010) and 95 CPCs (1978-2010). Median follow-up was 38 and 40 months, respectively. More than 75 % of CPCs were diagnosed before the age of 5 years, versus 48 % for CPPs. Sixty-five percent of CPCs and 57 % of CPPs occurred in males. In both groups at least 90 % of children underwent surgical resection. Gross total resection (GTR) was achieved in 67.0 % of CPCs and 63.6 % of CPPs. Almost 17 % of CPCs were treated with radiation versus only 0.9 % of CPPs. More than 98 % of patients with CPP were alive at the last follow-up, versus 62 % of CPC patients. For CPC, surgery was significantly associated with increased overall survival, but contrary to previous reports, extent of surgical resection was not associated with survival. Age, sex, race, and radiation treatment also had no effect on survival. This report, using the SEER datasets, corroborates many findings of previous smaller studies on CPTs. CPC occurs in younger children, with a male predominance, and a much worse prognosis than CPP. As such, these tumors have been treated aggressively with high rates of GTR and radiation treatment. Despite these treatments, overall survival for CPC remains poor.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.